{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:46:44Z","timestamp":1790862404943,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.nbd.2010.10.015","type":"journal-article","created":{"date-parts":[[2010,10,26]],"date-time":"2010-10-26T04:46:38Z","timestamp":1288068398000},"page":"436-444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6\/2 mice"],"prefix":"10.1016","volume":"41","author":[{"given":"Danielle A.","family":"Simmons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi A.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie C.","family":"Lauterborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Gall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2010.10.015_bb0005","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/39885","article-title":"Anterograde transport of brain-derived neurotrophic factor and its role in the brain","volume":"389","author":"Altar","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2010.10.015_bb0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.mcn.2008.04.007","article-title":"CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6\/2 mice","volume":"39","author":"Apostol","year":"2008","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.nbd.2010.10.015_bb0320","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nature02998","article-title":"Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death","volume":"14","author":"Arrasate","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2010.10.015_bb0015","doi-asserted-by":"crossref","first-page":"6809","DOI":"10.1073\/pnas.120166397","article-title":"Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice","volume":"97","author":"Bibb","year":"2000","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10.1016\/j.nbd.2010.10.015_bb0020","doi-asserted-by":"crossref","first-page":"7352","DOI":"10.1074\/jbc.M606508200","article-title":"AKT and CDK5\/p35 mediate brain-derived neurotrophic factor induction of DARPP-32 in medium size spiny neurons in vitro","volume":"282","author":"Bogush","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2010.10.015_bb0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.pneurobio.2005.06.003","article-title":"BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis","volume":"76","author":"Bramham","year":"2005","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.nbd.2010.10.015_bb0030","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.1523\/JNEUROSCI.1197-04.2004","article-title":"Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease","volume":"24","author":"Canals","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2010.10.015_bb0035","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1523\/JNEUROSCI.19-08-03248.1999","article-title":"Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation","volume":"19","author":"Carter","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2010.10.015_bb0040","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0166-2236(00)01609-X","article-title":"Transcriptional dysregulation in Huntington's disease","volume":"23","author":"Cha","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.nbd.2010.10.015_bb0045","doi-asserted-by":"crossref","first-page":"16685","DOI":"10.1073\/pnas.0707842104","article-title":"A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6\/2 transgenic mouse","volume":"104","author":"Chopra","year":"2007","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10.1016\/j.nbd.2010.10.015_bb0050","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1471-4159.2005.03029.x","article-title":"CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model","volume":"93","author":"Chou","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2010.10.015_bb0055","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1523\/JNEUROSCI.17-07-02295.1997","article-title":"Distribution of brain-derived neurotrophic factor (BDNF) protein and messenger RNA in the normal adult rat CNS: evidence for anterograde axonal transport","volume":"17","author":"Conner","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2010.10.015_bb0060","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","article-title":"Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation","volume":"90","author":"Davies","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.nbd.2010.10.015_bb0065","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.neuroscience.2007.11.044","article-title":"Cortical expression of brain derived neurotrophic factor and type-1 cannabinoid receptor after striatal excitotoxic lesions","volume":"152","author":"De March","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2010.10.015_bb0070","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1523\/JNEUROSCI.22-20-08942.2002","article-title":"Therapeutic effects of cystamine in a murine model of Huntington's disease","volume":"22","author":"Dedeoglu","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2010.10.015_bb0075","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.neuropharm.2008.08.001","article-title":"Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice","volume":"55","author":"Deltheil","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nbd.2010.10.015_bb0080","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.nbd.2010.10.015_bb0085","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1093\/hmg\/ddl210","article-title":"Green tea (\u2212)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models","volume":"15","author":"Ehrnhoefer","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2010.10.015_bb0090","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1523\/JNEUROSCI.20-12-04389.2000","article-title":"Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease","volume":"20","author":"Ferrante","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2010.10.015_bb0095","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1111\/j.1460-9568.2007.05918.x","article-title":"Repeated exposure to cocaine differently modulates BDNF mRNA and protein levels in rat striatum and prefrontal cortex","volume":"26","author":"Fumagalli","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.nbd.2010.10.015_bb0100","series-title":"Neurobiology of the Neurotrophins","first-page":"541","article-title":"Regulation of BDNF expression: multifaceted, region-specific control of a neuronal survival factor in the adult CNS","author":"Gall","year":"2000"},{"key":"10.1016\/j.nbd.2010.10.015_bb0105","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1471-4159.2007.05137.x","article-title":"Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice","volume":"105","author":"Gharami","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2010.10.015_bb0110","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.resp.2009.02.011","article-title":"Ampakine therapy to counter fentanyl-induced respiratory depression","volume":"168","author":"Greer","year":"2009","journal-title":"Respir. Physiol. Neurobiol."},{"key":"10.1016\/j.nbd.2010.10.015_bb0115","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1523\/JNEUROSCI.19-07-02522.1999","article-title":"Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology","volume":"19","author":"Gutekunst","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2010.10.015_bb0120","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/iub.111","article-title":"Protein misfolding inside cells: the case of huntingtin and Huntington's disease","volume":"60","author":"Hatters","year":"2008","journal-title":"IUBMB Life"},{"key":"10.1016\/j.nbd.2010.10.015_bb0125","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1471-4159.2002.00804.x","article-title":"The role of dopamine in motor symptoms in the R6\/2 transgenic mouse model of Huntington's disease","volume":"81","author":"Hickey","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2010.10.015_bb0130","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.neuroscience.2008.08.041","article-title":"Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice","volume":"157","author":"Hickey","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2010.10.015_bb0135","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ana.10094","article-title":"Environmental enrichment slows disease progression in R6\/2 Huntington's disease mice","volume":"51","author":"Hockly","year":"2002","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2010.10.015_bb0140","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s00221-005-2357-z","article-title":"Atypical diabetes associated with inclusion formation in the R6\/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents","volume":"166","author":"Hunt","year":"2005","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.nbd.2010.10.015_bb0145","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1006\/exnr.1997.6581","article-title":"Enhancement by an ampakine of memory encoding in humans","volume":"146","author":"Ingvar","year":"1997","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2010.10.015_bb0150","doi-asserted-by":"crossref","first-page":"18189","DOI":"10.1073\/pnas.0506375102","article-title":"FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease","volume":"102","author":"Jin","year":"2005","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10.1016\/j.nbd.2010.10.015_bb0155","article-title":"BDNF upregulation rescues synaptic plasticity in middle-aged ovariectomized rats","author":"Kramar","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.nbd.2010.10.015_bb0160","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1531-8249(199912)46:6<842::AID-ANA6>3.0.CO;2-O","article-title":"Huntington aggregates may not predict neuronal death in Huntington's disease","volume":"46","author":"Kuemmerle","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2010.10.015_bb0165","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/sj.embor.7400250","article-title":"Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series","volume":"5","author":"Landles","year":"2004","journal-title":"EMBO Rep."},{"key":"10.1016\/j.nbd.2010.10.015_bb0170","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1124\/jpet.103.053694","article-title":"Chronic elevation of brain-derived neurotrophic factor by ampakines","volume":"307","author":"Lauterborn","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.nbd.2010.10.015_bb0175","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.neuroscience.2008.12.018","article-title":"Ampakines cause sustained increases in brain-derived neurotrophic factor signaling at excitatory synapses without changes in AMPA receptor subunit expression","volume":"159","author":"Lauterborn","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2010.10.015_bb0180","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1126\/science.1065057","article-title":"Regulation of cell survival by secreted proneurotrophins","volume":"294","author":"Lee","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.nbd.2010.10.015_bb0185","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF02742437","article-title":"The early cellular pathology of Huntington's disease","volume":"20","author":"Li","year":"1999","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.nbd.2010.10.015_bb0190","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.nbd.2009.06.011","article-title":"Y-27632 improves rotarod performance and reduces huntingtin levels in R6\/2 mice","volume":"36","author":"Li","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2010.10.015_bb0195","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/hmg\/ddm362","article-title":"p21-activated kinase 1 promotes soluble mutant huntingtin self-interaction and enhances toxicity","volume":"17","author":"Luo","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2010.10.015_bb0200","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.coph.2003.09.009","article-title":"AMPA receptor modulators as cognitive enhancers","volume":"4","author":"Lynch","year":"2004","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.nbd.2010.10.015_bb0205","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.coph.2005.09.005","article-title":"Glutamate-based therapeutic approaches: ampakines","volume":"6","author":"Lynch","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.nbd.2010.10.015_bb0210","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.neuropharm.2006.07.027","article-title":"LTP consolidation: substrates, explanatory power, and functional significance","volume":"52","author":"Lynch","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nbd.2010.10.015_bb0215","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1523\/JNEUROSCI.5113-06.2007","article-title":"Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington's disease","volume":"27","author":"Lynch","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2010.10.015_bb0220","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.nbd.2010.10.015_bb0225","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nn2038","article-title":"Biosynthesis and processing of endogenous BDNF: CNS neurons store and secrete BDNF, not pro-BDNF","volume":"11","author":"Matsumoto","year":"2008","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.nbd.2010.10.015_bb0230","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0165-0270(96)02211-X","article-title":"Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion","volume":"73","author":"Matsuura","year":"1997","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.nbd.2010.10.015_bb0235","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0165-6147(00)01884-8","article-title":"Mouse models of Huntington's disease","volume":"23","author":"Menalled","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.nbd.2010.10.015_bb0240","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.nbd.2009.05.007","article-title":"Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models","volume":"35","author":"Menalled","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2010.10.015_bb0245","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1124\/jpet.103.049445","article-title":"LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease","volume":"306","author":"Murray","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.nbd.2010.10.015_bb0250","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.brainresbull.2008.10.007","article-title":"The detection and measurement of locomotor deficits in a transgenic mouse model of Huntington's disease are task- and protocol-dependent: influence of non-motor factors on locomotor function","volume":"78","author":"Pallier","year":"2009","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.nbd.2010.10.015_bb0255","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.expneurol.2007.10.015","article-title":"The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6\/2 Huntington's disease mouse model","volume":"210","author":"Peng","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2010.10.015_bb0260","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1152\/jn.00336.2006","article-title":"Restoration of long-term potentiation in middle-aged hippocampus after induction of brain-derived neurotrophic factor","volume":"96","author":"Rex","year":"2006","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.nbd.2010.10.015_bb0265","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1523\/JNEUROSCI.4037-06.2007","article-title":"Brain-derived neurotrophic factor promotes long-term potentiation-related cytoskeletal changes in adult hippocampus","volume":"27","author":"Rex","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2010.10.015_bb0270","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/glia.20526","article-title":"Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease","volume":"55","author":"Simmons","year":"2007","journal-title":"Glia"},{"key":"10.1016\/j.nbd.2010.10.015_bb0275","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1073\/pnas.0811228106","article-title":"Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice","volume":"106","author":"Simmons","year":"2009","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10.1016\/j.nbd.2010.10.015_bb0280","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbadis.2005.11.002","article-title":"Combination therapy using minocycline and coenzyme Q10 in R6\/2 transgenic Huntington's disease mice","volume":"1762","author":"Stack","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.nbd.2010.10.015_bb0285","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0168-9525(03)00074-X","article-title":"Transcriptional abnormalities in Huntington disease","volume":"19","author":"Sugars","year":"2003","journal-title":"Trends Genet."},{"key":"10.1016\/j.nbd.2010.10.015_bb0290","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/35008142","article-title":"Delaying the onset of Huntington's in mice","volume":"404","author":"van Dellen","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2010.10.015_bb0295","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nbd.2007.07.029","article-title":"Increased metabolism in the R6\/2 mouse model of Huntington's disease","volume":"29","author":"van der Burg","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2010.10.015_bb0300","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington's disease","volume":"44","author":"Vonsattel","year":"1985","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.nbd.2010.10.015_bb0305","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.pneurobio.2007.01.003","article-title":"Role of brain-derived neurotrophic factor in Huntington's disease","volume":"81","author":"Zuccato","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.nbd.2010.10.015_bb0310","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nrneurol.2009.54","article-title":"Brain-derived neurotrophic factor in neurodegenerative diseases","volume":"5","author":"Zuccato","year":"2009","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.nbd.2010.10.015_bb0315","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.phrs.2005.01.001","article-title":"Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery","volume":"52","author":"Zuccato","year":"2005","journal-title":"Pharmacol. Res."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996110003499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996110003499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:09:34Z","timestamp":1760850574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996110003499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0969996110003499"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2010.10.015","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6\/2 mice","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2010.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}